OBJECTIVE: The purpose of our study was to describe the characteristics of probably benign breast MRI lesions and determine how these characteristics could be used to define the MRI BI-RADS 3 category. MATERIALS AND METHODS: We prospectively collected morphology and kinetic data on lesions assessed as BI-RADS 3 in 2,569 consecutive breast MRI examinations from January 2003 through November 2006. The clinical indications for MRI, follow-up assessments, and pathology findings through May 2008 were collected from clinical records. Data were linked to the regional tumor registry to identify cases of malignancy in patients who did not follow-up at our institution. Frequency of BI-RADS 3 and cancer yield were calculated. Characteristics of probably benign lesions were analyzed for predictors of malignancy. RESULTS: Three hundred sixty-two lesions were assessed as BI-RADS 3 in 260 (10.1%) of 2,569 examinations in 236 patients. The 362 lesions included 168 (46%) foci, 132 (36%) nonmasslike enhancements, and 62 (17%) masses. Delayed kinetic information was available in 275 lesions. The most suspicious delayed kinetic enhancement was persistent in 164 (60%) of 275, plateau in 47 (17%) of 275, and washout in 64 (23%) of 275. The cancer yield in patients with a BI-RADS 3 assessment was two (0.85%) of 236; both were ductal carcinoma in situ lesions. There were no malignancies in the 69 foci with 100% persistent enhancement. CONCLUSION: The characteristics of BI-RADS 3 lesions were highly variable in our population, and the risk of malignancy was low (0.85%). Assigning foci with 100% persistent enhancement to the BI-RADS 2 category can decrease the frequency of BI-RADS 3 assessment and maintain a likelihood of malignancy in less than 2% of cases.
OBJECTIVE: The purpose of our study was to describe the characteristics of probably benign breast MRI lesions and determine how these characteristics could be used to define the MRI BI-RADS 3 category. MATERIALS AND METHODS: We prospectively collected morphology and kinetic data on lesions assessed as BI-RADS 3 in 2,569 consecutive breast MRI examinations from January 2003 through November 2006. The clinical indications for MRI, follow-up assessments, and pathology findings through May 2008 were collected from clinical records. Data were linked to the regional tumor registry to identify cases of malignancy in patients who did not follow-up at our institution. Frequency of BI-RADS 3 and cancer yield were calculated. Characteristics of probably benign lesions were analyzed for predictors of malignancy. RESULTS: Three hundred sixty-two lesions were assessed as BI-RADS 3 in 260 (10.1%) of 2,569 examinations in 236 patients. The 362 lesions included 168 (46%) foci, 132 (36%) nonmasslike enhancements, and 62 (17%) masses. Delayed kinetic information was available in 275 lesions. The most suspicious delayed kinetic enhancement was persistent in 164 (60%) of 275, plateau in 47 (17%) of 275, and washout in 64 (23%) of 275. The cancer yield in patients with a BI-RADS 3 assessment was two (0.85%) of 236; both were ductal carcinoma in situ lesions. There were no malignancies in the 69 foci with 100% persistent enhancement. CONCLUSION: The characteristics of BI-RADS 3 lesions were highly variable in our population, and the risk of malignancy was low (0.85%). Assigning foci with 100% persistent enhancement to the BI-RADS 2 category can decrease the frequency of BI-RADS 3 assessment and maintain a likelihood of malignancy in less than 2% of cases.
Authors: Amy Lynn Conners; Carrie B Hruska; Cindy L Tortorelli; Robert W Maxwell; Deborah J Rhodes; Judy C Boughey; Wendie A Berg Journal: Eur J Nucl Med Mol Imaging Date: 2012-06 Impact factor: 9.236
Authors: Christopher Loiselle; Peter R Eby; Janice N Kim; Kristine E Calhoun; Kimberly H Allison; Vijayakrishna K Gadi; Sue Peacock; Barry E Storer; David A Mankoff; Savannah C Partridge; Constance D Lehman Journal: Acad Radiol Date: 2014-01 Impact factor: 3.173
Authors: Bethany L Niell; Sara C Gavenonis; Tina Motazedi; Jessica Cott Chubiz; Elkan P Halpern; Elizabeth A Rafferty; Janie M Lee Journal: J Am Coll Radiol Date: 2014-04-29 Impact factor: 5.532
Authors: Matthias Meissnitzer; D David Dershaw; Kimberly Feigin; Blanca Bernard-Davila; Filipe Barra; Elizabeth A Morris Journal: Br J Radiol Date: 2017-05-25 Impact factor: 3.039
Authors: Maarten W Barentsz; Valentina Taviani; Jung M Chang; Debra M Ikeda; Kanae K Miyake; Suchandrima Banerjee; Maurice A A J van den Bosch; Brian A Hargreaves; Bruce L Daniel Journal: J Magn Reson Imaging Date: 2015-04-24 Impact factor: 4.813